Results 71 to 80 of about 252,496 (356)

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

open access: yesMolecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu   +18 more
wiley   +1 more source

DC fault current clearance coordinated control strategy for DC grid with hybrid MMC

open access: yesInternational Journal of Electrical Power & Energy Systems
For DC grid based on the hybrid modular multilevel converter (MMC), the traditional DC fault current clearance scheme takes a long time and greatly affects the active power transmission.
Shouqi Jiang   +4 more
doaj   +1 more source

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

open access: yesMolecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak   +8 more
wiley   +1 more source

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

open access: yesMolecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker   +16 more
wiley   +1 more source

Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia

open access: yesMolecular Oncology, EarlyView.
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad   +17 more
wiley   +1 more source

Fault detection and isolation [PDF]

open access: yes
Erroneous measurements in multisensor navigation systems must be detected and isolated. A recursive estimator can find fast growing errors; a least squares batch estimator can find slow growing errors. This process is called fault detection. A protection
Bernath, Greg
core   +1 more source

Dynamic process fault isolation by partial DPCA [PDF]

open access: yes, 2006
Principal component analysis (PCA) is a popular tool in fault detecting of the complex plant, but offers little support on fault isolation. Partial PCA (PPCA) is well developed for its capability of fault isolation utilizing a structured residual.
Li Rongyu, Rong Gang
core   +1 more source

Robust fault diagnosis of proton exchange membrane fuel cells using a Takagi-Sugeno interval observer approach [PDF]

open access: yes, 2016
In this paper, the problem of robust fault diagnosis of proton exchange membrane (PEM) fuel cells is addressed by introducing the Takagi-Sugeno (TS) interval observers that consider uncertainty in a bounded context, adapting TS observers to the so-called
Blesa Izquierdo, Joaquim   +4 more
core   +2 more sources

Feasibility of a ctDNA multigenic panel for non‐small‐cell lung cancer early detection and disease surveillance

open access: yesMolecular Oncology, EarlyView.
Plasma‐based detection of actionable mutations is a promising approach in lung cancer management. Analysis of ctDNA with a multigene NGS panel identified TP53, KRAS, and EGFR as the most frequently altered, with TP53 and KRAS in treatment‐naïve patients and TP53 and EGFR in previously treated patients.
Giovanna Maria Stanfoca Casagrande   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy